Dr. Ryan K. Brashear, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 777
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
IN license 01055019A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Franciscan Health Indianapolis Indianapolis, IN
Medical groups
- Dermatology Inc. (21 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 777
- Services billed
- 5,388
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 2,532 | 540 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,090 | 730 |
| Destruction of precancer skin growth, 1 growth | 983 | 673 |
| Biopsy of related skin growth, first growth | 422 | 365 |
| Destruction of skin growth, 1-14 growths | 112 | 103 |
| Biopsy of related skin growth, each additional growth | 111 | 94 |
| Established patient office or other outpatient visit, 10-19 minutes | 63 | 57 |
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 40 |
| New patient office or other outpatient visit, 30-44 minutes | 47 | 47 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 41 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 79 payments worth $1,359 in total to this clinician.
| AbbVie Inc. | $264 |
|---|---|
| Amgen Inc. | $167 |
| Galderma Laboratories, L.P. | $144 |
| Incyte Corporation | $128 |
| Lilly USA, LLC | $88.65 |
| Novartis Pharmaceuticals Corporation | $74.83 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.15 |
| UCB, Inc. | $64.17 |
| Food and Beverage | $1,359 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.